iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Average Rating of "Hold" from Analysts

Key Points

• iTeos Therapeutics has received a consensus rating of "Hold" from seven brokerages, with an average target price of $15.64.
• Major shareholder Bioventures 2018 L.P. sold 630,191 shares at an average price of $8.06, resulting in a 23.01% decrease in their position.
• Institutional investors hold 97.16% of iTeos Therapeutics stock, indicating significant interest from hedge funds and investment firms.

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) has earned an average recommendation of "Hold" from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $15.64.

Several research analysts recently issued reports on ITOS shares. Leerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Piper Sandler lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 21st. Raymond James Financial set a $12.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Leerink Partners reaffirmed a "market perform" rating and set a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Wedbush reissued an "outperform" rating and issued a $10.50 target price (down previously from $12.00) on shares of iTeos Therapeutics in a research note on Monday, July 21st.

Insiders Place Their Bets

In related news, Director David Hallal sold 38,228 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total value of $391,454.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michel Detheux sold 43,883 shares of the company's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $10.10, for a total value of $443,218.30. Following the completion of the transaction, the chief executive officer owned 135,903 shares of the company's stock, valued at $1,372,620.30. The trade was a 24.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,939,307 shares of company stock valued at $16,202,116. 12.50% of the stock is owned by insiders.

Institutional Investors Weigh In On iTeos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ITOS. RA Capital Management L.P. grew its stake in shares of iTeos Therapeutics by 74.4% in the 1st quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock valued at $21,785,000 after purchasing an additional 1,556,798 shares during the period. BVF Inc. IL boosted its holdings in iTeos Therapeutics by 32.3% during the first quarter. BVF Inc. IL now owns 3,075,000 shares of the company's stock worth $18,358,000 after buying an additional 750,000 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in iTeos Therapeutics by 342.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock worth $15,888,000 after buying an additional 1,601,477 shares during the last quarter. 683 Capital Management LLC boosted its holdings in iTeos Therapeutics by 90.6% during the first quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company's stock worth $10,448,000 after buying an additional 831,883 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in iTeos Therapeutics by 15.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company's stock worth $9,293,000 after acquiring an additional 163,880 shares during the last quarter. Hedge funds and other institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Trading Up 0.2%

Shares of iTeos Therapeutics stock traded up $0.03 on Monday, reaching $10.15. 478,858 shares of the company were exchanged, compared to its average volume of 922,879. The company has a 50-day moving average of $9.99 and a 200 day moving average of $8.05. iTeos Therapeutics has a one year low of $4.80 and a one year high of $18.13. The company has a market capitalization of $388.25 million, a price-to-earnings ratio of -3.34 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. Analysts predict that iTeos Therapeutics will post -3.49 earnings per share for the current year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.